Tackling Endocrine Resistance in Breast Cancer

Video

This video reviews the mechanisms of acquired and upfront endocrine resistance in estrogen receptor–positive breast cancer as well as research into strategies for overcoming this resistance.

In this video, Ingrid A. Mayer, MD, MSCI, of the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, discusses mechanisms of acquired and upfront endocrine resistance in estrogen receptor (ER)-positive breast cancer as well as research into strategies for overcoming these types of resistance, including targeting the mTOR and PI3K pathways.

Mayer spoke on this subject during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Related Content
An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.

Survival Outcomes Improve With TIL Presence in TNBC

April 16th 2024
Article

An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Durvalumab Combo Yields OS Benefit in Advanced Biliary Tract Cancer

Durvalumab Combo Yields OS Benefit in Advanced Biliary Tract Cancer

April 16th 2024
Article

The phase 3 TOPAZ-1 trial of durvalumab plus chemotherapy showed a significant benefit vs chemotherapy alone for patients with advanced biliary tract cancer.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Updates in Breast Cancer Care From the 41st Annual Miami Breast Cancer Conference

Updates in Breast Cancer Care From the 41st Annual Miami Breast Cancer Conference

April 15th 2024
Article

Several presentations from the 41st Annual Miami Breast Cancer Conference focused on new and evolving data in the space, according to Neil M. Iyengar, MD.

STARGLO Trial Meets OS End Point With Glofitamab in Relapsed/Refractory DLBCL

STARGLO Trial Meets OS End Point With Glofitamab in Relapsed/Refractory DLBCL

April 15th 2024
Article

Additional data and results from the phase 3 STARGLO trial of glofitamab for patients with relapsed/refractory diffuse large B-cell lymphoma will be presented at an upcoming medical meeting.